172 related articles for article (PubMed ID: 29100409)
1. Overcoming imatinib resistance conferred by the
Liu J; Bhadra M; Sinnakannu JR; Yue WL; Tan CW; Rigo F; Ong ST; Roca X
Oncotarget; 2017 Sep; 8(44):77567-77585. PubMed ID: 29100409
[TBL] [Abstract][Full Text] [Related]
2. The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia.
Rauzan M; Chuah CT; Ko TK; Ong ST
PLoS One; 2017; 12(3):e0174107. PubMed ID: 28301600
[TBL] [Abstract][Full Text] [Related]
3. Multi-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemia.
Soh SX; Lim JY; Huang JW; Jiang N; Yeoh AE; Ong ST
PLoS One; 2014; 9(8):e103435. PubMed ID: 25090024
[TBL] [Abstract][Full Text] [Related]
4. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.
Kiyota M; Kuroda J; Yamamoto-Sugitani M; Shimura Y; Nakayama R; Nagoshi H; Mizutani S; Chinen Y; Sasaki N; Sakamoto N; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
Apoptosis; 2013 Nov; 18(11):1437-1446. PubMed ID: 23851982
[TBL] [Abstract][Full Text] [Related]
5. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S
Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048
[TBL] [Abstract][Full Text] [Related]
6. The BCL2L11 deletion polymorphism is not associated with imatinib resistance in chronic myeloid leukemia patients: meta-analysis.
Xu J; Gu J; Zhao Y; Meng H; Du L; Zhang R; Jiang H; Luo J
Oncotarget; 2017 Nov; 8(58):99041-99048. PubMed ID: 29228749
[TBL] [Abstract][Full Text] [Related]
7. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
8. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.
Zhao M; Zhang Y; Cai W; Li J; Zhou F; Cheng N; Ren R; Zhao C; Li X; Ren S; Zhou C; Hirsch FR
Cancer; 2014 Aug; 120(15):2299-307. PubMed ID: 24737648
[TBL] [Abstract][Full Text] [Related]
9. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
[TBL] [Abstract][Full Text] [Related]
11. The roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinib-resistant chronic myeloid leukemia cells.
Bozkurt S; Özkan T; Özmen F; Baran Y; Sunguroğlu A; Kansu E
Hematology; 2013 Jul; 18(4):217-23. PubMed ID: 23394612
[TBL] [Abstract][Full Text] [Related]
12. Functional analysis of splicing mutations in the IDS gene and the use of antisense oligonucleotides to exploit an alternative therapy for MPS II.
Matos L; Gonçalves V; Pinto E; Laranjeira F; Prata MJ; Jordan P; Desviat LR; Pérez B; Alves S
Biochim Biophys Acta; 2015 Dec; 1852(12):2712-21. PubMed ID: 26407519
[TBL] [Abstract][Full Text] [Related]
13. The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy.
Ying HQ; Chen J; He BS; Pan YQ; Wang F; Deng QW; Sun HL; Liu X; Wang SK
Sci Rep; 2015 Jun; 5():11348. PubMed ID: 26076815
[TBL] [Abstract][Full Text] [Related]
14. Cis-acting intronic elements that regulate cartilage-specific alternative splicing of the type II collagen (Col2) pre-mRNA lie at or near splice site junction sequences flanking exon 2 of the gene.
Nishiyama T; Hatano H; Kurosaka M; Bolander ME; Sarkar G
J Bone Miner Res; 2003 Sep; 18(9):1716-22. PubMed ID: 12968682
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the expression of oncogene SRSF3 by blocking an exonic splicing suppressor with antisense oligonucleotides.
Guo J; Che X; Wang X; Jia R
RSC Adv; 2018 Feb; 8(13):7159-7163. PubMed ID: 35540349
[TBL] [Abstract][Full Text] [Related]
16. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
[TBL] [Abstract][Full Text] [Related]
18. [Treatment-free molecular remission achieved by combination therapy with imatinib and IFNα in CML with BIM deletion polymorphism relapsed after stop imatinib].
Katagiri S; Tauchi T; Umezu T; Saito Y; Suguro T; Asano M; Yoshizawa S; Kitahara T; Akahane D; Tanaka Y; Fujimoto H; Okabe S; Gotoh M; Ito Y; Ohyashiki JH; Ohyashiki K
Rinsho Ketsueki; 2015 Feb; 56(2):216-9. PubMed ID: 25765803
[TBL] [Abstract][Full Text] [Related]
19. Dual Fluorescence Splicing Reporter Minigene Identifies an Antisense Oligonucleotide to Skip Exon v8 of the
Fukushima S; Farea M; Maeta K; Rani AQM; Fujioka K; Nishio H; Matsuo M
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33266296
[TBL] [Abstract][Full Text] [Related]
20. Association between BIM deletion polymorphism and clinical outcome of EGFR-mutated NSCLC patient with EGFR-TKI therapy: A meta-analysis.
Ma JY; Yan HJ; Gu W
J Cancer Res Ther; 2015; 11(2):397-402. PubMed ID: 26148607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]